Sakar Healthcare Q2 FY27 Revenue Rises 52% to Rs 87.42 Crore

Sakar Healthcare Ltd reported Q2 FY27 revenue of Rs 87.42 crore, up 52% year-on-year, with EBITDA more than doubling to Rs 24.35 crore and its margin improving to 28% for the quarter ended September 30, 2026. The result matters because the company is scaling its oncology platform while reporting stronger operating profitability.

What did Sakar Healthcare report for Q2 FY27?

Sakar Healthcare Ltd reported revenue from operations of Rs 87.42 crore in Q2 FY27, compared with Rs 57.56 crore in Q2 FY26. The 51.9% year-on-year increase was accompanied by a 45% rise in first-half revenue to Rs 160.39 crore for H1 FY27.

Quarterly EBITDA rose 114% year-on-year to Rs 24.35 crore from Rs 11.35 crore. The EBITDA margin increased to 28% from 20% in the corresponding quarter of the previous year, indicating that profit growth exceeded the pace of revenue expansion during the period.

Profit after tax rose 149% year-on-year to Rs 11.31 crore in Q2 FY27 from Rs 4.54 crore in Q2 FY26. The PAT margin improved to 13% from 8%, according to the reported unaudited financial results for the quarter and half year ended September 30, 2026.

Which Q2 FY27 financial figures changed the most?

The largest reported year-on-year increase was in profit after tax, which rose 149%, followed by EBITDA growth of 114%. Revenue growth of nearly 52% provided the base for the improvement in operating and net profitability.

The margin movement is also notable. EBITDA margin expanded by 8 percentage points, from 20% to 28%, while PAT margin rose by 5 percentage points, from 8% to 13%. These measures show that the quarter's earnings improvement was not limited to higher sales.

How is oncology shaping Sakar Healthcare's business strategy?

Sakar's management said it is targeting oncology to contribute more than 60% of revenue within two to three years. The stated target places oncology at the centre of the company's planned revenue mix as it builds out this platform.

The supplied earnings-call highlights do not provide a separate oncology revenue figure for Q2 FY27 or a detailed product-wise split. As a result, the reported numbers establish the overall growth trend, while the precise current contribution of oncology cannot be quantified from the available information.

The company is an Ahmedabad-based drug manufacturer. Its quarterly results were announced as unaudited financial results for the quarter and half year ended September 30, 2026, with an earnings conference call held on October 27, 2026.

What did management say during the earnings call?

Management linked the quarterly performance to the company's operating progress and highlighted its oncology expansion objective. The disclosed call highlights specifically stated the goal of oncology contributing over 60% of revenue within two to three years.

The conference call concerned Q2 FY27 and H1 FY27 results. Sakar said an audio recording of the call was available on its website, while the transcript was to be shared with stock exchanges and made available on the company website at an appropriate time.

The available material does not disclose a revised annual revenue target, a margin target for FY27, or a formal capital-expenditure plan. Investors therefore have reported quarterly financial data and the oncology revenue-mix objective, but limited detail on the intermediate milestones management will use to track that objective.

What does the result mean for investors and the drug manufacturing sector?

For investors, the main reported development is the combination of 51.9% revenue growth and margin expansion. EBITDA rose faster than revenue, and PAT grew faster than EBITDA, resulting in a higher 28% EBITDA margin and 13% PAT margin in Q2 FY27.

The available source does not provide Sakar's share-price movement following the result, valuation measures, order book, export data, or segment-level sales. No conclusion on the market's immediate reaction can therefore be drawn from the reported information.

For industry observers, the results show the importance of product mix and execution in pharmaceutical manufacturing. Sakar's stated oncology target is material because it would alter the revenue composition if achieved, but the company has not disclosed current oncology sales or the specific path to reaching more than 60% of revenue.

Conclusion

Sakar delivered a strong Q2 FY27 performance, reporting revenue of Rs 87.42 crore, EBITDA of Rs 24.35 crore and profit after tax of Rs 11.31 crore. The year-on-year gains in both revenue and margins indicate that profitability improved alongside sales during the quarter ended September 30, 2026.

The next issue to watch is management's execution toward its plan for oncology to contribute more than 60% of revenue within two to three years. Investors will also look for future disclosures on oncology's current revenue contribution, the trajectory of H1 growth through the second half, and the timing of the full call transcript.